Mtss Vs Allorisk Stratifier for Early Mortality Prediction after Allo-HCT in Myelofibrosis: Evidence from a Single-Center Treosulfan-Based Cohort | Synapse
March 3, 2026
Mtss Vs Allorisk Stratifier for Early Mortality Prediction after Allo-HCT in Myelofibrosis: Evidence from a Single-Center Treosulfan-Based Cohort
Key Points
Early mortality prediction improves outcomes for individuals undergoing allo-HCT.
The study reveals a significant difference in prediction accuracy between the Mtss and Allorisk stratifiers.
Observational analysis using a cohort of myelofibrosis patients treated with treosulfan provides insights into mortality risks.
Findings may influence clinical decisions, but caution is needed due to the single-center design.